Chickenpox Vaccine Industry to Witness 6.7% Growth, Reaching $4.93 Billion by 2029

 

The chickenpox vaccine market size has grown strongly in recent years. It will grow from $3.57 billion in 2024 to $3.8 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%.  The growth in the historic period can be attributed to vaccine development, regulatory approvals, disease incidence, vaccination policies, public health initiatives.

The chickenpox vaccine market size is expected to see strong growth in the next few years. It will grow to $4.93 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%.  The growth in the forecast period can be attributed to public perception and trust, pandemic preparedness, research and development, emerging market demand, healthcare infrastructure development. Major trends in the forecast period include vaccine education campaigns, adverse event monitoring, vaccine pricing strategies, advanced innovation, use of AI.

Get Your Free Sample of The Global Chickenpox Vaccine Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8581&type=smp

How has the chickenpox vaccine market evolved, and what factors have shaped its growth?
The rising prevalence of chickenpox disease is expected to propel the growth of the chickenpox vaccine market going forward. Chickenpox disease refers to a severe infectious disease caused by the varicella-zoster virus (VZV) that causes a fluid-filled rash with an itchy rash. Increased cases of chickenpox necessitate more varicella vaccine immunization, thus, increasing demand for chickenpox vaccines. For instance, in October 2023, according to a report published by the National Library of Medicine (NLM), a US-based biomedical library, that a study of GP consultations for chickenpox from September 2016 to December 2022 found an average weekly rate of 3.4 per 100,000 people in England, with regular peaks between weeks 13 and 15 each year. During the COVID-19 pandemic, typical epidemic peaks were absent, likely due to social distancing and lockdowns. However, in 2022, consultation rates were higher among children under 1 year old compared to pre-pandemic years, indicating disrupted transmission patterns. Therefore, the rising prevalence of chickenpox disease is driving the growth of the chickenpox vaccine market.

What are the major segments of the chickenpox vaccine market?
The chickenpox vaccine market covered in this report is segmented –
1) By Vaccine: Monovalent Varicella Vaccine, Combination Varicella Vaccine
2) By Application: Mumps, Measles, Rubella, And Varicella Immunization, Herpes Zoster Immunization, Chickenpox Vaccination
3) By End-Users: Hospitals, Clinics, Other End-Users

Subsegments:
1) By Monovalent Varicella Vaccine: Live Attenuated Varicella Vaccine
2) By Combination Varicella Vaccine: Measles, Mumps, Rubella, And Varicella (MMRV) Vaccine

Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/chickenpox-vaccine-global-market-report

Which companies dominate the chickenpox vaccine market?
Major companies operating in the chickenpox vaccine market include  Merck & Co., Sanofi Pasteur, Takeda Pharmaceutical Company Limited, CSL Limited, Pfizer Inc., Seqirus, Serum Institute of India Pvt. Ltd., Bharat Biotech, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Shenzhen Kangtai Biological Products Co., Ltd., Chongqing Zhifei Biological Products Co., Ltd., Beijing Minhai Biotechnology Co., Ltd., Adimmune Corporation, Biological E. Limited, Walvax Biotechnology Co., Ltd., Zydus Cadila, Indian Immunologicals Ltd., Panacea Biotec Ltd., Bio Farma, PT Kalbe Farma Tbk, CanSino Biologics

How will evolving trends contribute to the growth of the chickenpox vaccine market?
Novel drug developments are the key trend gaining popularity in the chickenpox vaccine market. Major companies operating in the market are developing novel drugs with improved efficacy, innovative derivatives, and others to sustain their position in the market. For instance, in November 2022, Sinovac Biotech Ltd., a China-based company focused on research, development, and manufacturing of vaccines, stated that the World Health Organization (WHO) granted it prequalification for its live attenuated chickenpox (varicella) vaccine, which is the world's first varicella vaccine to receive prequalification. The Oka strain is the source of the varicella vaccine, which is produced in the exclusive Human Diploid Cell (SV-1 strain) of SINOVAC. This cell is created by cultivating and harvesting the virus, adding stabilizers, and freeze-drying it. A phase III efficacy trial found that the seroconversion rate of the vaccine-embedded children group, aged 1 to 12 years old, was 97.1%; the vaccine's efficacy against varicella and against breakthrough varicella was 87.1% and 89.2%, respectively. The vaccine offers 100 percent defense against mild and serious conditions.

What are the key regional dynamics of the chickenpox vaccine market, and which region leads in market share?
The countries covered in the chickenpox vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Does The Chickenpox Vaccine Market Report 2025 Offer?
The chickenpox vaccine market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.

Chickenpox vaccines are biological preparations that stimulate the cell-mediated immune response and prepare it to fight future infections caused by viruses by triggering IgG-mediated production of antibodies against varicella-zoster-specific pathogens that enter the body. The varicella-zoster virus causes chickenpox, which is a highly contagious disease (VZV).

Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8581

About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.

Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model